Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature
Brian P. Lee, Jennifer L. Dodge, Norah A. Terrault
Hepatology (2023) Vol. 79, Iss. 3, pp. 666-673
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 26
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David Le, Thomas C. Baez, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 2, pp. 235-246
Open Access | Times Cited: 24
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
Brian P. Lee, Katie Witkiewitz, Jessica L. Mellinger, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 9, pp. 626-645
Open Access | Times Cited: 19
Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
Donghee Kim, Karn Wijarnpreecha, George Cholankeril, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 1, pp. 33-42
Closed Access | Times Cited: 17
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050
Phuc Le, Moosa Tatar, Srinivasan Dasarathy, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2454707-e2454707
Open Access | Times Cited: 5
Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
Nobuharu Tamaki, Takefumi Kimura, Shun‐ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 1, pp. 61-69
Closed Access | Times Cited: 14
Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study
Takao Miwa, Satoko Tajirika, Nanako Imamura, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1158-1158
Open Access | Times Cited: 13
Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA
Alexander H. Yang, Monica A. Tincopa, Federica Tavaglione, et al.
Gut (2024) Vol. 73, Iss. 12, pp. 2045-2053
Open Access | Times Cited: 13
Metabolic characteristics of patients with MetALD: Caveats of a new definition
Erin Petrie, Meagan Gray, Fernando Bril
Liver International (2024) Vol. 44, Iss. 11, pp. 2929-2938
Closed Access | Times Cited: 11
Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population
Haoxuan Zou, Xiaopu Ma, Wen Pan, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 9
Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort
Joo Hyun Oh, Sang Bong Ahn, Seon Cho, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 8
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria
Luis Antonio Díaz, Jeffrey V. Lazarus, Eduardo Fuentes‐López, et al.
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 8
Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD
Aleksander Krag, Nikolaj Torp, Zobair M. Younossi, et al.
˜The œLancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 1
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease
Shang‐Chin Huang, Tung‐Hung Su, Tai‐Chung Tseng, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 7
Machine learning across multiple imaging and biomarker modalities in the UK Biobank improves genetic discovery for liver fat accumulation
Hari Somineni, Sumit Mukherjee, David Amar, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease
Qingxia Huang, S. U. Qadri, Hua Bian, et al.
Journal of Hepatology (2024)
Open Access | Times Cited: 5
Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors
Francisco Capinha, Sofia Carvalhana, Helena Cortez‐Pinto
Digestive Diseases and Sciences (2025)
Open Access
Patterns of dietary supplement use among United States patients with steatotic liver disease: Vitamins, minerals and botanicals
Melinda Wang, Gabrielle Jutras, Giuseppe Cullaro, et al.
World Journal of Hepatology (2025) Vol. 17, Iss. 3
Closed Access
Concordance of vibration-controlled transient elastography and magnetic resonance elastography for fibrosis staging in patients with metabolic dysfunction-associated steatotic liver disease
Arpita Mathur, Efe Ozkaya, Sonam Rosberger, et al.
European Radiology (2025)
Closed Access
Metabolic dysfunction-associated steatotic liver disease and increased risk of atrial fibrillation in the elderly: A longitudinal cohort study
Yehua Tang, Jianling Fan, Xingyun Hou, et al.
IJC Heart & Vasculature (2025) Vol. 58, pp. 101676-101676
Closed Access
Bioelectrical impedance analysis parameters are superior to liver enzymes in predicting metabolic dysfunction-associated steatotic liver disease in young adults
Kyungchul Song, Yu‐Jin Kwon, Eun Ju Lee, et al.
Internal and Emergency Medicine (2025)
Closed Access
Metabolic Dysfunction-Associated Steatotic Liver Disease and Polycystic Ovary Syndrome: A Complex Interplay
Konstantinos Arvanitakis, Elena Chatzikalil, Georgios Kalopitas, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4243-4243
Open Access | Times Cited: 4
Lingguizhugan oral solution alleviates MASLD by regulating bile acids metabolism and the gut microbiota through activating FXR/TGR5 signaling pathways
Jiahua Wang, Juan Zang, Yu Yang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Diet quality and physical activity affect metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and etiology-associated steatohepatitis, and compensated advanced chronic liver disease among United States adults: NHANES 2017–2020
Peng Wang, Bo Xia, Shuang Wang
Frontiers in Nutrition (2025) Vol. 11
Open Access
Page 1 - Next Page

Scroll to top